首開股份(600376.SH):擬發行65億元定向債務融資工具
格隆匯 6 月 15日丨首開股份(600376.SH)公佈,公司第九屆董事會第二十五次會議召開,審議通過《關於公司擬發行65億元定向債務融資工具的議案》;
公司擬向中國銀行間市場交易商協會申請註冊發行65億元定向債務融資工具(PPN),期限不超過5年。主承銷商為中信建投證券股份有限公司,聯席主承銷商為光大銀行股份有限公司和杭州銀行股份有限公司,固定利率,擬用於項目開發建設、償還公司債務和補充流動資金及適用的法律法規允許的其他用途。無需擔保。
此次定向債務融資工具(PPN)在完成必要的發行手續後,採取分期發行的方式,具體發行期數及各期發行規模根據公司資金需求情況和發行時市場情況確定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.